The relative risk of developing cancer was found to be higher in multiple sclerosis patients who more frequently switched between disease-modifying treatments, according to a study.
In addition, researchers found ... Read more
Multiple sclerosis (MS) patients in Canada are more likely to comply with their treatment plan and less likely to discontinue the use of the oral disease-modifying treatment Gilenya (fingolimod), compared ... Read more
Levels of proposed biomarker neurofilament light chain (NfL) are associated with therapeutic effects of disease-modifying treatments (DMTs) in relapsing-remitting multiple sclerosis (RRMS) patients, according to a real-world study. Study findings also ... Read more
The National Multiple Sclerosis Society reported that the Patient-Centered Outcomes Research Institute (PCORI) has granted nearly $20 million in funding to four research projects assessing various multiple sclerosis (MS) ... Read more